The observed alteration of Treg subpopulations (decreased nTreg and increased mTreg) in our cohort of AIS patients was contrary to a previous report (Ruhnau et al., 2016), which showed unchanged nTreg and loss of activated Treg (CD4 + FoxP3 + CD39+), but had a relatively small sample size (48 patients and 26 controls) and unmatched baseline characteristics. This evidence concerns the gene FOXP3 and androgen insensitivity syndrome.